...
首页> 外文期刊>Rare tumors >Prognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients
【24h】

Prognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients

机译:手术联合放疗治疗成人软组织肉瘤的预后因素:回顾性单中心研究,共164例患者

获取原文

摘要

The aim of the present study is to assess the disease profile, outcome and prognostic factors in patients treated with surgery combined with radiotherapy (RT), with or without chemotherapy (CXT), for soft-tissue sarcoma (STS) in a multidisciplinary setting. One hundred and sixty-four patients with STS treated between 1980 and 2010 at the Centre Hospitalier Universitaire Vaudois were enrolled in this retrospective study. Seventy-six percent of patients underwent postoperative RT with (24%), or without (52%) CXT, 15% preoperative RT with (5%), or without (10%) CXT, surgery alone (7%), or RT alone (2%) with or without CXT. The median follow-up was 60 months (range 6-292). Local failure was observed in 18%, and distant failure in 21% of the patients. Overall survival (OS), disease-free survival (DFS), local control (LC) and distant metastases-free survival (DMFS) were 88%, 68%, 83%, and 79% at 5 years, and 80%, 56%, 76%, and 69% at 10 years, respectively. In univariate analyses, favorable prognostic factors for OS, DFS, and DMFS were tumor size 6 cm or less, World Health Organization (WHO)/Zubrod score 0, and stage 2 or less. Age and superficial tumors were favorable only for OS and DMFS respectively. STS involving the extremities had a better outcome regarding DFS and LC. Histological grade 2 or less was favorable for DFS, DMFS, and LC. Radical surgery was associated with better LC and DMFS. RT dose more than 60 Gy was favorable for OS, DFS, and LC. In multivariate analyses, independent factors were age for OS; tumor size for OS, DFS and DMFS; WHO/Zubrod score for OS, DFS and LC; hemoglobin level for DFS; site for DFS and LC; tumor depth for DMFS; histological grade for DFS and LC; surgical procedure for LC and DMFS; and RT dose for OS. This study confirms that in a multidisciplinary setting, STS have a fairly good prognosis. A number of prognostic and predictive factors, including the role of surgery combined with RT, were identified. Regarding RT, a dose of more than 60 Gy was associated with a better outcome, at the price of a higher toxicity. We could not demonstrate a superiority of preoperative RT over postoperative RT.
机译:本研究的目的是评估多学科情况下软组织肉瘤(STS)联合放疗(RT),有无化疗(CXT)的手术治疗患者的疾病谱,结局和预后因素。这项回顾性研究纳入了1980年至2010年间由沃杜伊大学中心医院治疗的164例STS患者。百分之七十六的患者在接受术后CRT(24%)或不接受CXT(52%)的情况下接受手术,接受术前(15%)CXT(5%)或不接受(10%)CXT的患者接受RT,仅接受手术(7%)或RT单独(2%)有或没有CXT。中位随访时间为60个月(范围6-292)。 18%的患者观察到局部衰竭,而21%的患者观察到远处衰竭。 5年总生存率(OS),无病生存率(DFS),局部控制(LC)和无远处转移生存率(DMFS)分别为88%,68%,83%和79%,而80%,56 10年时分别为%,76%和69%。在单因素分析中,OS,DFS和DMFS的有利预后因素是肿瘤尺寸6 cm或更小,世界卫生组织(WHO)/ Zubrod评分0和2期或更小。年龄和浅表肿瘤分别仅对OS和DMFS有利。关于DFS和LC,涉及四肢的STS效果更好。 DFS,DMFS和LC的组织学等级为2或更低。根治性手术与更好的LC和DMFS有关。 RT剂量大于60 Gy对OS,DFS和LC有利。在多变量分析中,独立因素是OS的年龄。 OS,DFS和DMFS的肿瘤大小; WHO / Zubrod在OS,DFS和LC方面的得分; DFS的血红蛋白水平; DFS和LC的站点; DMFS的肿瘤深度; DFS和LC的组织学等级; LC和DMFS的手术程序;和RT剂量用于OS。这项研究证实,在多学科的情况下,STS的预后较好。确定了许多预后和预测因素,包括手术联合放疗的作用。关于RT,超过60 Gy的剂量具有更好的结果,但毒性更高。我们不能证明术前放疗优于术后放疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号